Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

In Vivo Bone Effects of a Novel Bisphosphonate-EP4a Conjugate Drug (C3) for Reversing Osteoporotic Bone Loss in an Ovariectomized Rat Model.

Sheikh Z, Chen G, Al-Jaf F, Thévenin M, Banks K, Glogauer M, Young RN, Grynpas MD.

JBMR Plus. 2019 Nov 9;3(12):e10237. doi: 10.1002/jbm4.10237. eCollection 2019 Dec.

2.

A Novel Anabolic Conjugate (C3) in the Matrix of Dicalcium Phosphate Onlay Block Grafts for Achieving Vertical Bone Augmentation: An Experimental Study on Rabbit Calvaria.

Sheikh Z, Chen G, Thévenin M, Young RN, Grynpas MD, Glogauer M.

Int J Oral Maxillofac Implants. 2019 July/August;34(4):e51–e63. doi: 10.11607/jomi.7236. Epub 2019 Feb 4.

PMID:
30716148
3.

A new quinoline-based chemical probe inhibits the autophagy-related cysteine protease ATG4B.

Bosc D, Vezenkov L, Bortnik S, An J, Xu J, Choutka C, Hannigan AM, Kovacic S, Loo S, Clark PGK, Chen G, Guay-Ross RN, Yang K, Dragowska WH, Zhang F, Go NE, Leung A, Honson NS, Pfeifer TA, Gleave M, Bally M, Jones SJ, Gorski SM, Young RN.

Sci Rep. 2018 Aug 3;8(1):11653. doi: 10.1038/s41598-018-29900-x.

4.

Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.

Chin S, Hung M, Won A, Wu YS, Ahmadi S, Yang D, Elmallah S, Toutah K, Hamilton CM, Young RN, Viirre RD, Yip CM, Bear CE.

Mol Pharmacol. 2018 Aug;94(2):917-925. doi: 10.1124/mol.118.112177. Epub 2018 Jun 14.

PMID:
29903751
5.

Targeting therapeutics to bone by conjugation with bisphosphonates.

Young RN, Grynpas MD.

Curr Opin Pharmacol. 2018 Jun;40:87-94. doi: 10.1016/j.coph.2018.03.010. Epub 2018 Apr 4. Review.

PMID:
29626715
6.

Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis.

Xie H, Chen G, Young RN.

J Med Chem. 2017 Aug 24;60(16):7012-7028. doi: 10.1021/acs.jmedchem.6b00951. Epub 2017 Aug 10.

PMID:
28699744
7.

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.

Lallous N, Leblanc E, Munuganti RS, Hassona MD, Nakouzi NA, Awrey S, Morin H, Roshan-Moniri M, Singh K, Lawn S, Yamazaki T, Adomat HH, Andre C, Daugaard M, Young RN, Guns ES, Rennie PS, Cherkasov A.

Mol Cancer Ther. 2016 Dec;15(12):2936-2945. Epub 2016 Oct 7.

8.

Further investigation of inhibitors of MRSA pyruvate kinase: Towards the conception of novel antimicrobial agents.

Labrière C, Gong H, Finlay BB, Reiner NE, Young RN.

Eur J Med Chem. 2017 Jan 5;125:1-13. doi: 10.1016/j.ejmech.2016.09.018. Epub 2016 Sep 9.

PMID:
27643559
9.

Precision autophagy: Will the next wave of selective autophagy markers and specific autophagy inhibitors feed clinical pipelines?

Lebovitz CB, DeVorkin L, Bosc D, Rothe K, Singh J, Bally M, Jiang X, Young RN, Lum JJ, Gorski SM.

Autophagy. 2015;11(10):1949-52. doi: 10.1080/15548627.2015.1078962.

10.

Corrigendum: The promise and peril of chemical probes.

Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, Cravatt B, Dahlin JL, Dhanak D, Edwards AM, Frederiksen M, Frye SV, Gray N, Grimshaw CE, Hepworth D, Howe T, Huber KV, Jin J, Knapp S, Kotz JD, Kruger RG, Lowe D, Mader MM, Marsden B, Mueller-Fahrnow A, Müller S, O'Hagan RC, Overington JP, Owen DR, Rosenberg SH, Ross R, Roth B, Schapira M, Schreiber SL, Shoichet B, Sundström M, Superti-Furga G, Taunton J, Toledo-Sherman L, Walpole C, Walters MA, Willson TM, Workman P, Young RN, Zuercher WJ.

Nat Chem Biol. 2015 Nov;11(11):887. doi: 10.1038/nchembio1115-887c. No abstract available.

PMID:
26485080
11.

In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.

Hu S, Liu CC, Chen G, Willett T, Young RN, Grynpas MD.

Osteoporos Int. 2016 Feb;27(2):797-808. doi: 10.1007/s00198-015-3284-x. Epub 2015 Aug 14.

PMID:
26272313
12.

The promise and peril of chemical probes.

Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, Cravatt B, Dahlin JL, Dhanak D, Edwards AM, Frederiksen M, Frye SV, Gray N, Grimshaw CE, Hepworth D, Howe T, Huber KV, Jin J, Knapp S, Kotz JD, Kruger RG, Lowe D, Mader MM, Marsden B, Mueller-Fahrnow A, Müller S, O'Hagan RC, Overington JP, Owen DR, Rosenberg SH, Roth B, Ross R, Schapira M, Schreiber SL, Shoichet B, Sundström M, Superti-Furga G, Taunton J, Toledo-Sherman L, Walpole C, Walters MA, Willson TM, Workman P, Young RN, Zuercher WJ.

Nat Chem Biol. 2015 Aug;11(8):536-41. doi: 10.1038/nchembio.1867. No abstract available. Erratum in: Nat Chem Biol. 2015 Aug;11(8):541. Roth, Brian [Corrected to Roth, Bryan] and Frederiksen, Mathias [Added]. Nat Chem Biol. 2015 Nov;11(11):887.

13.

Development of fluorescent peptide substrates and assays for the key autophagy-initiating cysteine protease enzyme, ATG4B.

Vezenkov L, Honson NS, Kumar NS, Bosc D, Kovacic S, Nguyen TG, Pfeifer TA, Young RN.

Bioorg Med Chem. 2015 Jul 1;23(13):3237-47. doi: 10.1016/j.bmc.2015.04.064. Epub 2015 Apr 28.

PMID:
25979376
14.

Determination of the rat in vivo pharmacokinetic profile of a bone-targeting dual-action pro-drug for treatment of osteoporosis.

Chen G, Arns S, Young RN.

Bioconjug Chem. 2015 Jun 17;26(6):1095-103. doi: 10.1021/acs.bioconjchem.5b00160. Epub 2015 May 15.

PMID:
25945831
15.

Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer.

Munuganti RS, Hassona MD, Leblanc E, Frewin K, Singh K, Ma D, Ban F, Hsing M, Adomat H, Lallous N, Andre C, Jonadass JP, Zoubeidi A, Young RN, Guns ET, Rennie PS, Cherkasov A.

Chem Biol. 2014 Nov 20;21(11):1476-85. doi: 10.1016/j.chembiol.2014.09.012.

16.

Novel EP4 receptor agonist-bisphosphonate conjugate drug (C1) promotes bone formation and improves vertebral mechanical properties in the ovariectomized rat model of postmenopausal bone loss.

Liu CC, Hu S, Chen G, Georgiou J, Arns S, Kumar NS, Young RN, Grynpas MD.

J Bone Miner Res. 2015 Apr;30(4):670-80. doi: 10.1002/jbmr.2382.

17.

Development of fluorescent substrates and assays for the key autophagy-related cysteine protease enzyme, ATG4B.

Nguyen TG, Honson NS, Arns S, Davis TL, Dhe-Paganon S, Kovacic S, Kumar NS, Pfeifer TA, Young RN.

Assay Drug Dev Technol. 2014 Apr;12(3):176-89. doi: 10.1089/adt.2013.561.

18.

Discovery and optimization of a new class of pyruvate kinase inhibitors as potential therapeutics for the treatment of methicillin-resistant Staphylococcus aureus infections.

Kumar NS, Dullaghan EM, Finlay BB, Gong H, Reiner NE, Jon Paul Selvam J, Thorson LM, Campbell S, Vitko N, Richardson AR, Zoraghi R, Young RN.

Bioorg Med Chem. 2014 Mar 1;22(5):1708-25. doi: 10.1016/j.bmc.2014.01.020. Epub 2014 Jan 24.

19.

Autophagy: from structure to metabolism to therapeutic regulation.

Jardon MA, Rothe K, Bortnik S, Vezenkov L, Jiang X, Young RN, Lum JJ, Gorski SM.

Autophagy. 2013 Dec;9(12):2180-2. doi: 10.4161/auto.26378. Epub 2013 Sep 30.

PMID:
24201076
20.

Optimization and structure-activity relationships of a series of potent inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase as novel antimicrobial agents.

Kumar NS, Amandoron EA, Cherkasov A, Finlay BB, Gong H, Jackson L, Kaur S, Lian T, Moreau A, Labrière C, Reiner NE, See RH, Strynadka NC, Thorson L, Wong EW, Worrall L, Zoraghi R, Young RN.

Bioorg Med Chem. 2012 Dec 15;20(24):7069-82. doi: 10.1016/j.bmc.2012.10.002. Epub 2012 Oct 17.

PMID:
23141418
21.

Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis.

Arns S, Gibe R, Moreau A, Monzur Morshed M, Young RN.

Bioorg Med Chem. 2012 Mar 15;20(6):2131-40. doi: 10.1016/j.bmc.2012.01.024. Epub 2012 Jan 31.

PMID:
22341574
22.

Cheminformatics-driven discovery of selective, nanomolar inhibitors for staphylococcal pyruvate kinase.

Axerio-Cilies P, See RH, Zoraghi R, Worral L, Lian T, Stoynov N, Jiang J, Kaur S, Jackson L, Gong H, Swayze R, Amandoron E, Kumar NS, Moreau A, Hsing M, Strynadka NC, McMaster WR, Finlay BB, Foster LJ, Young RN, Reiner NE, Cherkasov A.

ACS Chem Biol. 2012 Feb 17;7(2):350-9. doi: 10.1021/cb2003576. Epub 2011 Nov 21.

PMID:
22066782
23.

Identification of pyruvate kinase in methicillin-resistant Staphylococcus aureus as a novel antimicrobial drug target.

Zoraghi R, See RH, Axerio-Cilies P, Kumar NS, Gong H, Moreau A, Hsing M, Kaur S, Swayze RD, Worrall L, Amandoron E, Lian T, Jackson L, Jiang J, Thorson L, Labriere C, Foster L, Brunham RC, McMaster WR, Finlay BB, Strynadka NC, Cherkasov A, Young RN, Reiner NE.

Antimicrob Agents Chemother. 2011 May;55(5):2042-53. doi: 10.1128/AAC.01250-10. Epub 2011 Feb 28.

24.

Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.

Isabel E, Mellon C, Boyd MJ, Chauret N, Deschênes D, Desmarais S, Falgueyret JP, Gauthier JY, Khougaz K, Lau CK, Léger S, Levorse DA, Li CS, Massé F, Percival MD, Roy B, Scheigetz J, Thérien M, Truong VL, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2011 Feb 1;21(3):920-3. doi: 10.1016/j.bmcl.2010.12.070. Epub 2010 Dec 19.

PMID:
21232956
25.

Inhibition of autophagosome formation by the benzoporphyrin derivative verteporfin.

Donohue E, Tovey A, Vogl AW, Arns S, Sternberg E, Young RN, Roberge M.

J Biol Chem. 2011 Mar 4;286(9):7290-300. doi: 10.1074/jbc.M110.139915. Epub 2010 Dec 30.

26.

Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.

Gallant M, Aspiotis R, Day S, Dias R, Dubé D, Dubé L, Friesen RW, Girard M, Guay D, Hamel P, Huang Z, Lacombe P, Laliberté S, Lévesque JF, Liu S, Macdonald D, Mancini J, Nicholson DW, Styhler A, Townson K, Waters K, Young RN, Girard Y.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6387-93. doi: 10.1016/j.bmcl.2010.09.087. Epub 2010 Sep 21.

PMID:
20933411
27.

The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.

Aspiotis R, Deschênes D, Dubé D, Girard Y, Huang Z, Laliberté F, Liu S, Papp R, Nicholson DW, Young RN.

Bioorg Med Chem Lett. 2010 Sep 15;20(18):5502-5. doi: 10.1016/j.bmcl.2010.07.076. Epub 2010 Jul 21.

PMID:
20709547
28.

The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.

Isabel E, Bateman KP, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Gauthier JY, Lamontagne S, Lau CK, Léger S, LeRiche T, Lévesque JF, Li CS, Massé F, McKay DJ, Mellon C, Nicoll-Griffith DA, Oballa RM, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):887-92. doi: 10.1016/j.bmcl.2009.12.083. Epub 2009 Dec 28.

PMID:
20061146
29.

Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.

Lacombe P, Chauret N, Claveau D, Day S, Deschênes D, Dubé D, Gallant M, Girard Y, Huang Z, Laliberté F, Lévesque JF, Liu S, Macdonald D, Mancini JA, Masson P, Nicholson DW, Nicoll-Griffith DA, Salem M, Styhler A, Young RN.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5266-9. doi: 10.1016/j.bmcl.2009.03.105. Epub 2009 Mar 26.

PMID:
19640717
30.

Design and synthesis of an all-in-one 3-(1,1-difluoroprop-2-ynyl)-3H-diazirin-3-yl functional group for photo-affinity labeling.

Kumar NS, Young RN.

Bioorg Med Chem. 2009 Aug 1;17(15):5388-95. doi: 10.1016/j.bmc.2009.06.048. Epub 2009 Jun 27.

PMID:
19604700
31.

Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein.

Macdonald D, Brideau C, Chan CC, Falgueyret JP, Frenette R, Guay J, Hutchinson JH, Perrier H, Prasit P, Riendeau D, Tagari P, Thérien M, Young RN, Girard Y.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2023-7. doi: 10.1016/j.bmcl.2008.01.105. Epub 2008 Feb 2.

PMID:
18276139
32.

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Kimmel DB, Lamontagne S, Léger S, LeRiche T, Li CS, Massé F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. doi: 10.1016/j.bmcl.2007.12.047. Epub 2008 Jan 15.

PMID:
18226527
33.

Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.

Gallant M, Chauret N, Claveau D, Day S, Deschênes D, Dubé D, Huang Z, Lacombe P, Laliberté F, Lévesque JF, Liu S, Macdonald D, Mancini J, Masson P, Mastracchio A, Nicholson D, Nicoll-Griffith DA, Perrier H, Salem M, Styhler A, Young RN, Girard Y.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1407-12. doi: 10.1016/j.bmcl.2008.01.004. Epub 2008 Jan 8.

PMID:
18207397
34.

The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells.

Cherukuri DP, Chen XB, Goulet AC, Young RN, Han Y, Heimark RL, Regan JW, Meuillet E, Nelson MA.

Exp Cell Res. 2007 Aug 15;313(14):2969-79. Epub 2007 Jun 22.

35.

L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.

Huang Z, Dias R, Jones T, Liu S, Styhler A, Claveau D, Otu F, Ng K, Laliberte F, Zhang L, Goetghebeur P, Abraham WM, Macdonald D, Dubé D, Gallant M, Lacombe P, Girard Y, Young RN, Turner MJ, Nicholson DW, Mancini JA.

Biochem Pharmacol. 2007 Jun 15;73(12):1971-81. Epub 2007 Mar 16.

PMID:
17428447
36.

Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent binding.

Lévesque JF, Day SH, Chauret N, Seto C, Trimble L, Bateman KP, Silva JM, Berthelette C, Lachance N, Boyd M, Li L, Sturino CF, Wang Z, Zamboni R, Young RN, Nicoll-Griffith DA.

Bioorg Med Chem Lett. 2007 Jun 1;17(11):3038-43. Epub 2007 Mar 23.

PMID:
17418572
37.

Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).

Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, Aubin Y, Bateman KP, Chauret N, Day SH, Lévesque JF, Seto C, Silva JH, Trimble LA, Carriere MC, Denis D, Greig G, Kargman S, Lamontagne S, Mathieu MC, Sawyer N, Slipetz D, Abraham WM, Jones T, McAuliffe M, Piechuta H, Nicoll-Griffith DA, Wang Z, Zamboni R, Young RN, Metters KM.

J Med Chem. 2007 Feb 22;50(4):794-806.

PMID:
17300164
38.

In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites.

Nicoll-Griffith DA, Seto C, Aubin Y, Lévesque JF, Chauret N, Day S, Silva JM, Trimble LA, Truchon JF, Berthelette C, Lachance N, Wang Z, Sturino C, Braun M, Zamboni R, Young RN.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):301-4. Epub 2006 Oct 25.

PMID:
17095220
39.

Identification of an indole series of prostaglandin D2 receptor antagonists.

Sturino CF, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, Brideau C, Cauchon E, Carriere MC, Denis D, Greig G, Kargman S, Lamontagne S, Mathieu MC, Sawyer N, Slipetz D, O'Neill G, Wang Z, Zamboni R, Metters KM, Young RN.

Bioorg Med Chem Lett. 2006 Jun 1;16(11):3043-8. Epub 2006 Mar 10.

PMID:
16529930
40.

Lack of clinical efficacy of a phosphodiesterase-4 inhibitor for treatment of heaves in horses.

Lavoie JP, Pasloske K, Joubert P, Cordeau ME, Mancini J, Girard Y, Friesen RW, Frenette R, Blouin M, Young RN, Hickey G.

J Vet Intern Med. 2006 Jan-Feb;20(1):175-81.

41.

Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.

Palmer JT, Bryant C, Wang DX, Davis DE, Setti EL, Rydzewski RM, Venkatraman S, Tian ZQ, Burrill LC, Mendonca RV, Springman E, McCarter J, Chung T, Cheung H, Janc JW, McGrath M, Somoza JR, Enriquez P, Yu ZW, Strickley RM, Liu L, Venuti MC, Percival MD, Falgueyret JP, Prasit P, Oballa R, Riendeau D, Young RN, Wesolowski G, Rodan SB, Johnson C, Kimmel DB, Rodan G.

J Med Chem. 2005 Dec 1;48(24):7520-34.

PMID:
16302794
42.

Approaching criticality in polymer-polymer systems.

Carelli C, Jones RA, Young RN, Cubitt R, Dalgliesh R, Schmid F, Sferrazza M.

Phys Rev E Stat Nonlin Soft Matter Phys. 2005 Sep;72(3 Pt 1):031807. Epub 2005 Sep 19.

PMID:
16241473
43.

Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.

Macdonald D, Mastracchio A, Perrier H, Dubé D, Gallant M, Lacombe P, Deschênes D, Roy B, Scheigetz J, Bateman K, Li C, Trimble LA, Day S, Chauret N, Nicoll-Griffith DA, Silva JM, Huang Z, Laliberté F, Liu S, Ethier D, Pon D, Muise E, Boulet L, Chan CC, Styhler A, Charleson S, Mancini J, Masson P, Claveau D, Nicholson D, Turner M, Young RN, Girard Y.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5241-6. Epub 2005 Sep 15.

PMID:
16168647
44.

Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.

Friesen RW, Ducharme Y, Ball RG, Blouin M, Boulet L, Côté B, Frenette R, Girard M, Guay D, Huang Z, Jones TR, Laliberté F, Lynch JJ, Mancini J, Martins E, Masson P, Muise E, Pon DJ, Siegl PK, Styhler A, Tsou NN, Turner MJ, Young RN, Girard Y.

J Med Chem. 2003 Jun 5;46(12):2413-26.

PMID:
12773045
45.

Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.

Ducharme Y, Friesen RW, Blouin M, Côté B, Dubé D, Ethier D, Frenette R, Laliberté F, Mancini JA, Masson P, Styhler A, Young RN, Girard Y.

Bioorg Med Chem Lett. 2003 Jun 2;13(11):1923-6.

PMID:
12749899
46.

Discovery of a potent and selective agonist of the prostaglandin EP4 receptor.

Billot X, Chateauneuf A, Chauret N, Denis D, Greig G, Mathieu MC, Metters KM, Slipetz DM, Young RN.

Bioorg Med Chem Lett. 2003 Mar 24;13(6):1129-32.

PMID:
12643927
47.

Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.

Guay D, Hamel P, Blouin M, Brideau C, Chan CC, Chauret N, Ducharme Y, Huang Z, Girard M, Jones TR, Laliberté F, Masson P, McAuliffe M, Piechuta H, Silva J, Young RN, Girard Y.

Bioorg Med Chem Lett. 2002 Jun 3;12(11):1457-61.

PMID:
12031319
48.

Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro.

Tomita M, Li X, Okada Y, Woodiel FN, Young RN, Pilbeam CC, Raisz LG.

Bone. 2002 Jan;30(1):159-63. Erratum in: Bone. 2003 Jun;32(6):725.

PMID:
11792579
49.

Discovery of montelukast: a once-a-day oral antagonist of leukotriene D4 for the treatment of chronic asthma.

Young RN.

Prog Med Chem. 2001;38:249-77. Review. No abstract available.

PMID:
11774796
50.

Stereoselective total synthesis of (+/-)-thielocin A1beta.

Génisson Y, Tyler PC, Ball RG, Young RN.

J Am Chem Soc. 2001 Nov 21;123(46):11381-7.

PMID:
11707114

Supplemental Content

Loading ...
Support Center